Dan‐Qing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dan‐Qing Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Gui‐Ge Wang
Department of Thoracic Surgery Peking Union Medical College Hospital Beijing China
1 shared publicationJia‐Qi Zhang
Department of Thoracic Surgery Peking Union Medical College Hospital Beijing China
1 shared publicationTian‐Ge Wang
Chinese Academy of Medical Sciences Plastic Surgery Hospital Beijing China
1 shared publicationYan‐Qing Wang
Department of Thoracic Surgery Peking Union Medical College Hospital Beijing China
1 shared publicationZhong‐Xing Bing
Department of Thoracic Surgery Peking Union Medical College Hospital Beijing China
1 shared publication
Latest Publications
- Open Access
- 18 August 2021
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 37 (12) , 1027-1037
Silencing of circ_0000517 suppresses proliferation, glycolysis, and glutamine decomposition of non‐small cell lung cancer by modulating miR‐330‐5p/YY1 signal pathway
In recent years, circular RNA (circRNA) has been found to be involved in a variety of cancer processes. More and more attention has been paid to the research of circRNA in lung cancer. This study aims to investigate whether circ_0000517 affected the physiology of non‐small cell lung cancer (NSCLC) and the underlying mechanism. The results demonstrated that circ_0000517 was highly expressed in lung cancer tissues and cells, and overexpression of circ_0000517 was negatively correlated with the prognosis of NSCLC patients. Silencing of circ_0000517 significantly inhibited the proliferation, glycolysis, and glutamine decomposition of NSCLC cells in vitro and repressed the growth of xenografted tumors in vivo. Moreover, knockdown of circ_0000517 attenuated the expression of PCNA, HK2, LDHA, ASCT2, and GLS1. Further study found that circ_0000517 targeted miR‐330‐5p and miR‐330‐5p targeted YY1. In addition, miR‐330‐5p inhibitor reversed inhibition of cancer cell proliferation, glycolysis, and glutamine decomposition induced by si‐circ_0000517. In conclusion, our study revealed that silencing of circ_0000517 improved the progression of NSCLC through regulating miR‐330‐5p/YY1 axis.
- 18 August 2021
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 37 (12) , 1027-1037
Open AccessSilencing of circ_0000517 suppresses proliferation, glycolysis, and glutamine decomposition of non‐small cell lung cancer by modulating miR‐330‐5p/YY1 signal pathway
In recent years, circular RNA (circRNA) has been found to be involved in a variety of cancer processes. More and more attention has been paid to the research of circRNA in lung cancer. This study aims to investigate whether circ_0000517 affected the physiology of non‐small cell lung cancer (NSCLC) and the underlying mechanism. The results demonstrated that circ_0000517 was highly expressed in lung cancer tissues and cells, and overexpression of circ_0000517 was negatively correlated with the prognosis of NSCLC patients. Silencing of circ_0000517 significantly inhibited the proliferation, glycolysis, and glutamine decomposition of NSCLC cells in vitro and repressed the growth of xenografted tumors in vivo. Moreover, knockdown of circ_0000517 attenuated the expression of PCNA, HK2, LDHA, ASCT2, and GLS1. Further study found that circ_0000517 targeted miR‐330‐5p and miR‐330‐5p targeted YY1. In addition, miR‐330‐5p inhibitor reversed inhibition of cancer cell proliferation, glycolysis, and glutamine decomposition induced by si‐circ_0000517. In conclusion, our study revealed that silencing of circ_0000517 improved the progression of NSCLC through regulating miR‐330‐5p/YY1 axis.